Comparison

LY2608204 European Partner

Item no. S2155-5
Manufacturer Selleckchem
CASRN 1234703-40-2
Amount 5 mg
Quantity options 10 mg 1 g 10 g 10 mM/1 ml 200 mg 5 mg 50 mg 5 g
Category
Type Inhibitors
Specific against other
Smiles C1CCC(CC1)C2CC2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC=C(S5)SCCN6CCCC6
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias 1234703-40-2'
Similar products LY2608204
Available
Manufacturer - Targets
GK
Storage Conditions
2 years -80 in solvent
Molecular Weight
559, 81
Administration
Orally, rats are given a 2 g/kg oral glucose bolus 2 hours after LY2608204 administration.
Animal Models
Male Wistar rats at a weight of 225-250 g
Dosages
1, 3, 6, 10, 20 and 30 mg/kg
Formulation
LY2608204 is suspended in a 1:1 mixture of solutol/ethanol in a bath sonicator (10% of total volume). The obtained suspension is then diluted with 9 volumes of 10% aqueous solutol solution.
IC50
42 nM (EC50) [1], 42 nM (EC50) [1], 42 nM (EC50) [1], 42 nM (EC50) [1], 42 nM (EC50) [1], 42 nM (EC50) [1]
In vitro
LY2608204 activates glucokinase (GK) with EC50 of 42 nM at 10 mM glucose with a concentration dependent manner at lower glucose concentrations. LY2608204 also stimulates glucose metabolism in rat insulinoma INS1-E cells with EC50 of 579 nM. [1]
In vivo
LY2608204 decreases plasma glucose in a dose-dependent manner at both fasted and postprandial glucose levels. A maximal lowering of glucose AUC versus the untreated control group is observed with the high dose (30 mg/kg) and represents a 42% decrease. Interpolation of the data show that a 20% glucose AUC decrease occurs at an average LY2608204 concentration of 99 ng/mL (179 nM) in plasma, corresponding to a 6.9 mg/kg LY2608204 dose. The in vivo blood brain barrier permeability of LY2608204 results in a mean brain/plasma ratio of 0.17 five minutes post-dose with a mean total brain level of 0.539 nmol/g. [1]
Kinase Assay
Glucokinase assay, The human islet GK isoform is expressed in E. coli as (His)6-tagged fusion protein and purified with metal chelate affinity chromatography. After purification the enzyme is stored in aliquots at concentration 0.8 mg/mL in 25 mM sodium phosphate, 150 mM sodium chloride, 100 mM imidazole, 1 mM dithiothreitol, 50% glycerol at 80 C. The assay is performed in flat bottom 96-well plates in a final incubation volume of 100 uL. The incubation mixture consists of 25 mM HEPES (pH7.4), 50 mM potassiumchloride, 2.5 mM magnesiumchloride, 2 mM dithiothreitol, 4 U/mL glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides, 5 mM ATP, 1 mM NAD and a set concentration of glucose. LY2608204 is dissolved in DMSO and then added to the reaction mixture giving the final DMSO concentration of 10%. The reaction is initiated by addition of 20 uL GK and runs for 20 min at 37 C. The amount of formed NADH is measured as an increase in absorbance at 340 nm using a microplate reader. Absorbance values are used for EC50 calculations.
Solubility (25C)
DMSO 112 mg/mL, Water <1 mg/mL, Ethanol 35 mg/mL
Information
LY2608204 activates glucokinase (GK) with EC50 of 42 nM. Phase 2.
Chemical Name
(1R, 2S)-2-cyclohexyl-1-(4-(cyclopropylsulfonyl)phenyl)-N-(5-(2-(pyrrolidin-1-yl)ethylthio)thiazol-2-yl)cyclopropanecarboxamide

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?